-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 N7hJNyI/jILpFZ121yE8Dktw7RaDGIxmb73DoW2g9L0roPgI5+c1nBNkKPcyeF0u
 FnpuygIjj3L1ALBF5vfQXQ==

<SEC-DOCUMENT>0001127855-07-000647.txt : 20071226
<SEC-HEADER>0001127855-07-000647.hdr.sgml : 20071225
<ACCEPTANCE-DATETIME>20071226094838
ACCESSION NUMBER:		0001127855-07-000647
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20071224
FILED AS OF DATE:		20071226
DATE AS OF CHANGE:		20071226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SINOVAC BIOTECH LTD
		CENTRAL INDEX KEY:			0001084201
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			B9
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32371
		FILM NUMBER:		071325186

	BUSINESS ADDRESS:	
		STREET 1:		39 SHANGDI XI ROAD
		STREET 2:		HAIDIAN DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100085
		BUSINESS PHONE:		86-10-82890088

	MAIL ADDRESS:	
		STREET 1:		39 SHANGDI XI ROAD
		STREET 2:		HAIDIAN DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NET FORCE SYSTEMS INC
		DATE OF NAME CHANGE:	19991110
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sinovac6k122407.htm
<DESCRIPTION>SINOVAC BIOTECH LTD. 6K, 12.24.07
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">

<html>

	<head>
		<title>Untitled Page</title>
	</head>

	<body bgcolor="#ffffff">
		<p align="left"><br>
			<br>
			<br>
			<br>
		</p>
		<div align="center">
			<p>FORM 6-K<br>
				<br>
					SECURITIES AND EXCHANGE COMMISSION<br>
					Washington D.C. 20549<br>
				<br>
					REPORT OF FOREIGN ISSUER<br>
					PURSUANT TO RULE 13a-16 OR 15d-16 OF THE<br>
					SECURITIES EXCHANGE ACT OF 1934<br>
				<br>
				For the month of December 2007<br>
					--------------<br>
					Commission File Number: 001-32371<br>
				----------<br>
				<br>
				SINOVAC BIOTECH LTD.<br>
				<br>
					39 Shangdi Xi Road<br>
					Haidian District<br>
				Beijing 100085, People&rsquo;s Republic of China<br>
					(Address of principal executive offices)<br>
				<br>
			</p>
		</div>
		<p align="left">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</p>
		<p align="center">Form 20-F&nbsp;&nbsp;&nbsp;&nbsp; ___<u>X</u>____&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; _________</p>
		<p align="left">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):________________<br>
			<br>
			Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):________________<br>
			<br>
			Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</p>
		<p align="center">Yes&nbsp; ________&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;No&nbsp;&nbsp; ___<u>X</u>____</p>
		<p align="left">If &quot;Yes&quot; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):</p>
		<p align="center">82-&nbsp; ____<u>N/A</u>____</p>
		<br>
		<br>
		<br>
		<br>
		<hr>
		<br>
		<br>
		<br>
		<br>
		<div align="center">
			<p>SINOVAC BIOTECH LTD.<br>
				<br>
					Form 6-K<br>
				<br>
					TABLE OF CONTENTS<br>
				<br>
				<br>
			</p>
		</div>
		<div align="left">
			<p>Signature&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3<br>Exhibit 99.1 &#150; Press Release&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
				<br>
			</p>
		</div>
		<div align="center">
			<p>2</p>
		</div>
		<hr>
		<br>
		<br>
		<br>
		<br>
		<p align="center">SIGNATURE</p>
		<p align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br>
			<br>
			<br>
			&nbsp;SINOVAC BIOTECH LTD.<br>
			<br>
			<br>&nbsp;By:&nbsp; <u>&nbsp;&nbsp;&nbsp;/s/ Weidong Yin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br>
			</u>&nbsp;Name: &nbsp;Weidong Yin&nbsp;<br>
			Title:&nbsp;Chief Executive Officer, President<br>
			Date: &nbsp;December 24, 2007<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
			<br>
		</p>
		<div align="center">
			<p>3</p>
		</div>
		<hr>
		<p><b></b></p>
		<p><b></b></p>
	</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sinovacexh99_1.htm
<DESCRIPTION>SINOVAC BIOTECH LTD. 6K, PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">

<html>

	<head>
		<title>Untitled Page</title>
	</head>

	<body bgcolor="#ffffff">
		<p><br>
			<br>
			<br>
		</p>
		<div align="right">
			<p><u>Exhibit 99.1<br>
					<br>
					<br>
				</u></p>
		</div>
		<div align="center">
			<p><b><font size="+1">Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine<br>
					</font><br>
				</b></p>
		</div>
		<div align="left">
			<p><b>Beijing &#150; December 24, 2007 </b>&#150; Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced positive top-line<b> </b>results of completed Phase II clinical trial of its pandemic influenza (H5N1) whole viron inactivated vaccine. The stratified, randomized, double-blind trial of the vaccine was designed to assess the safety and immunogenicity of the vaccine.&nbsp;<br>
				<br>
				Sinovac received approval from the China State Food and Drug Administration (SFDA) in April 2007 to conduct Phase Ib and II trials of the H5N1 whole viron vaccine and Phase I and Phase II trials of the H5N1 split vaccine.&nbsp;<br>
				<br>
				The Phase II trial of the H5N1 whole viron inactivated vaccine was conducted by Beijing Centers for Disease Control and Prevention. It included 402 volunteers, between the ages of 18 and 60, who were each vaccinated with two doses of 5 ug, 10 ug or 15 ug. The preliminary results of the trials suggested that each of the three dosages can induce varying degrees of immune response. In particular, the anti-HI seroconversion rate, the increasing GMT and protection rate of the H5N1 whole viron inactivated vaccines for the 10ug and 15ug dosages reached the EMEA evaluation standards of seasonal flu vaccines, which is an indication of good immunogenicity of the vaccine. The trial result did not show any serious adverse reaction among volunteers, suggesting the vaccine&rsquo;s good safety profile.<br>
				<br>
				In addition, Sinovac recently completed the phase I clinical trial of the split H5N1 vaccine. The result of vaccinations on children, adults and elderly with candidate vaccines of different dosage indicated that the split H5N1 vaccine is safe for human use.<br>
				<br>
				Mr. Weidong Yin, Chairman, President and CEO, stated, &ldquo;We are very pleased with the achievements of our team that led to the development of a pandemic influenza vaccine. After Phase II clinical trials of the whole viron H5N1 vaccine, the vaccine dosages and schedule can now be determined. This accomplishment is a further step towards providing an effective prevention option for the government in the event of a future influenza pandemic. In addition to&nbsp; announcing the positive results of the Phase II clinical trial for the H5N1 whole viron vaccine, we are making progress on the clinical trials for the H5N1 split vaccine, which should provide additional prevention options in the face of a future influenza pandemic.&rdquo;<br>
				<br>
				<br>
				<br>
				<br>
			</p>
		</div>
		<hr>
		<br>
		<br>
		<br>
		<br>
		Sinovac commenced the development of a pandemic influenza vaccine in February 2004. In June 2006, the Phase I clinical trial results indicated good immunogenicity and safety, which results were published in &ldquo;The Lancet&rdquo; in September 2006.<br>
		<br>
		<b>About Sinovac <br>
			<br>
		</b>Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive&#153; (hepatitis A), Bilive&#153; (combined hepatitis A and B) and Anflu&#153; (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, and Japanese encephalitis. Additional information about Sinovac is available on its website, <u>http://www.sinovac.com</u>. To be added to our distribution list, please email: <u>info@sinovac.com</u>.<br>
		<br>
		<b>Safe Harbor Statement <br>
			<br>
		</b>This announcement contains forward-looking statements. These statements are made under the &quot;safe harbor&quot; provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as &quot;will,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;future,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates&quot; and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except
 as required under applicable law.<br>
		<br>
		<table border="0" cellspacing="0" cellpadding="0">
			<tr>
				<td valign="top" width="283">
					<p>Contact Information:<br>
						Helen G. Yang<br>
						Sinovac Biotech Ltd.<br>
						Phone: +86-10-82890088 Ext. 871<br>
						Fax: +86-10-62966910<br>
						Email: <u>info@sinovac.com </u></p>
				</td>
				<td valign="top" width="324">
					<p>Investors/Media:<br>
						Stephanie Carrington/Janine McCargo<br>
						The Ruth Group<br>
						(646) 536-7017/7033<br>
						scarrington@theruthgroup.com<br>
						jmccargo@theruthgroup.com</p>
				</td>
			</tr>
		</table>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<br>
		<div align="center">
			<p>2</p>
		</div>
		<hr>
	</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
